Effect of the α-glucosidase inhibitor acarbose on control of glycemia in dogs with naturally acquired diabetes mellitus

Richard W Nelson, Jane Robertson, Edward C Feldman, Carolyn Briggs

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective - To evaluate effect of acarbose on control of glycemia in dogs with diabetes mellitus. Design - Prospective randomized crossover controlled trial. Animals - 5 dogs with naturally acquired diabetes mellitus. Procedures - Dogs were treated with acarbose and placebo for 2 months each: in 1 of 2 randomly assigned treatment sequences. Dogs that weighed ≤ 10 kg (22 b; n = 3) or > 10 kg (2) were given 25 or 50 mg of acarbose, respectively, at each meal for 2 weeks, then 50 or 100 mg of acarbose, respectively, at each meal for 6 weeks, with a 1-month interval between treatments. Caloric intake, type of insulin, and frequency of insulin administration were kept constant, and insulin dosage was adjusted as needed to maintain control of glycemia. Serum glucose concentrations, blood glycosylated hemoglobin concentration, and serum fructosamine concentration were determined. Results - Significant differences in mean body weight and daily insulin dosage among dogs treated with acarbose and placebo were not found. Mean preprandial serum glucose concentration, 8-hour mean serum glucose concentration, and blood glycosylated hemoglobin concentration were significantly lower in dogs treated with insulin and acarbose, compared with insulin and placebo. Semisoft to watery feces developed in 3 dogs treated with acarbose. Conclusions and Clinical Relevance - Acarbose may be useful as an adjunctive treatment in diabetic dogs in which cause for poor glycemic control cannot be identified, and insulin treatment alone is ineffective.

Original languageEnglish (US)
Pages (from-to)1265-1269
Number of pages5
JournalJournal of the American Veterinary Medical Association
Volume216
Issue number8
StatePublished - Apr 15 2000

Fingerprint

acarbose
Acarbose
Glucosidases
glucosidases
diabetes mellitus
blood glucose
Diabetes Mellitus
Dogs
insulin
Insulin
dogs
blood serum
placebos
Placebos
Glycosylated Hemoglobin A
Serum
glucose
Meals
Blood Glucose
hemoglobin

ASJC Scopus subject areas

  • veterinary(all)

Cite this

@article{26e79e0d7cf34a7bb844e79a4c954b31,
title = "Effect of the α-glucosidase inhibitor acarbose on control of glycemia in dogs with naturally acquired diabetes mellitus",
abstract = "Objective - To evaluate effect of acarbose on control of glycemia in dogs with diabetes mellitus. Design - Prospective randomized crossover controlled trial. Animals - 5 dogs with naturally acquired diabetes mellitus. Procedures - Dogs were treated with acarbose and placebo for 2 months each: in 1 of 2 randomly assigned treatment sequences. Dogs that weighed ≤ 10 kg (22 b; n = 3) or > 10 kg (2) were given 25 or 50 mg of acarbose, respectively, at each meal for 2 weeks, then 50 or 100 mg of acarbose, respectively, at each meal for 6 weeks, with a 1-month interval between treatments. Caloric intake, type of insulin, and frequency of insulin administration were kept constant, and insulin dosage was adjusted as needed to maintain control of glycemia. Serum glucose concentrations, blood glycosylated hemoglobin concentration, and serum fructosamine concentration were determined. Results - Significant differences in mean body weight and daily insulin dosage among dogs treated with acarbose and placebo were not found. Mean preprandial serum glucose concentration, 8-hour mean serum glucose concentration, and blood glycosylated hemoglobin concentration were significantly lower in dogs treated with insulin and acarbose, compared with insulin and placebo. Semisoft to watery feces developed in 3 dogs treated with acarbose. Conclusions and Clinical Relevance - Acarbose may be useful as an adjunctive treatment in diabetic dogs in which cause for poor glycemic control cannot be identified, and insulin treatment alone is ineffective.",
author = "Nelson, {Richard W} and Jane Robertson and Feldman, {Edward C} and Carolyn Briggs",
year = "2000",
month = "4",
day = "15",
language = "English (US)",
volume = "216",
pages = "1265--1269",
journal = "Journal of the American Veterinary Medical Association",
issn = "0003-1488",
publisher = "American Veterinary Medical Association",
number = "8",

}

TY - JOUR

T1 - Effect of the α-glucosidase inhibitor acarbose on control of glycemia in dogs with naturally acquired diabetes mellitus

AU - Nelson, Richard W

AU - Robertson, Jane

AU - Feldman, Edward C

AU - Briggs, Carolyn

PY - 2000/4/15

Y1 - 2000/4/15

N2 - Objective - To evaluate effect of acarbose on control of glycemia in dogs with diabetes mellitus. Design - Prospective randomized crossover controlled trial. Animals - 5 dogs with naturally acquired diabetes mellitus. Procedures - Dogs were treated with acarbose and placebo for 2 months each: in 1 of 2 randomly assigned treatment sequences. Dogs that weighed ≤ 10 kg (22 b; n = 3) or > 10 kg (2) were given 25 or 50 mg of acarbose, respectively, at each meal for 2 weeks, then 50 or 100 mg of acarbose, respectively, at each meal for 6 weeks, with a 1-month interval between treatments. Caloric intake, type of insulin, and frequency of insulin administration were kept constant, and insulin dosage was adjusted as needed to maintain control of glycemia. Serum glucose concentrations, blood glycosylated hemoglobin concentration, and serum fructosamine concentration were determined. Results - Significant differences in mean body weight and daily insulin dosage among dogs treated with acarbose and placebo were not found. Mean preprandial serum glucose concentration, 8-hour mean serum glucose concentration, and blood glycosylated hemoglobin concentration were significantly lower in dogs treated with insulin and acarbose, compared with insulin and placebo. Semisoft to watery feces developed in 3 dogs treated with acarbose. Conclusions and Clinical Relevance - Acarbose may be useful as an adjunctive treatment in diabetic dogs in which cause for poor glycemic control cannot be identified, and insulin treatment alone is ineffective.

AB - Objective - To evaluate effect of acarbose on control of glycemia in dogs with diabetes mellitus. Design - Prospective randomized crossover controlled trial. Animals - 5 dogs with naturally acquired diabetes mellitus. Procedures - Dogs were treated with acarbose and placebo for 2 months each: in 1 of 2 randomly assigned treatment sequences. Dogs that weighed ≤ 10 kg (22 b; n = 3) or > 10 kg (2) were given 25 or 50 mg of acarbose, respectively, at each meal for 2 weeks, then 50 or 100 mg of acarbose, respectively, at each meal for 6 weeks, with a 1-month interval between treatments. Caloric intake, type of insulin, and frequency of insulin administration were kept constant, and insulin dosage was adjusted as needed to maintain control of glycemia. Serum glucose concentrations, blood glycosylated hemoglobin concentration, and serum fructosamine concentration were determined. Results - Significant differences in mean body weight and daily insulin dosage among dogs treated with acarbose and placebo were not found. Mean preprandial serum glucose concentration, 8-hour mean serum glucose concentration, and blood glycosylated hemoglobin concentration were significantly lower in dogs treated with insulin and acarbose, compared with insulin and placebo. Semisoft to watery feces developed in 3 dogs treated with acarbose. Conclusions and Clinical Relevance - Acarbose may be useful as an adjunctive treatment in diabetic dogs in which cause for poor glycemic control cannot be identified, and insulin treatment alone is ineffective.

UR - http://www.scopus.com/inward/record.url?scp=0034655121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034655121&partnerID=8YFLogxK

M3 - Article

VL - 216

SP - 1265

EP - 1269

JO - Journal of the American Veterinary Medical Association

JF - Journal of the American Veterinary Medical Association

SN - 0003-1488

IS - 8

ER -